• Bladder cancer: survival outcomes similar with robotic vs open cystectomy

    Findings from a large multinational trial of 9.7K patients.

  • Urothelial cancer: enfortumab vedotin active after platinum, anti-PD-1/L1 therapy

    Favorable phase 2 findings validate Nectin-4 as a therapeutic target.

  • Optimal first-line therapy in cisplatin-ineligible metastatic urothelial cancer

    Large cohort study compares immunotherapy and carboplatin-based chemotherapy.

  • Erdafitinib nets 40% response rate in advanced urothelial cancer

    Findings led to accelerated FDA approval.

  • Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer

    NICE recommends special arrangements for clinical use

  • Bladder cancer: frailty predicts higher in-hospital mortality after surgery

    ICU-level complications, nonhome discharge.

  • Cochrane: is robotic cystectomy preferable for bladder cancer?

    A meta-analysis of 5 randomized trials.

  • Promising new treatment for advanced refractory solid tumours
    Promising new treatment for advanced refractory solid tumours

    Further studies of the treatment for HER2-low breast cancer and other HER2-expressing cancers are planned.

  • Bladder cancer: higher lung cancer risk warrants screening

    Screening guidelines do not include transitional cell carcinoma as a risk factor.

  • ASCO 2019 — Enfortumab vedotin yields 44% response rate in advanced urothelial cancer

    Successful in patients resistant to checkpoint inhibitors.

  • Bladder cancer: ipilimumab-heavy immunotherapy combo offers best response

    Updated results from CheckMate 032.

  • Human papillomavirus and the risk of urothelial carcinoma of the bladder

    Results from a case-control study.

  • Urothelial cancer: 2-year data support pembrolizumab over chemotherapy

    Long-term KEYNOTE-045 data maintain consistency.

  • FDA approves erdafitinib for bladder cancer

    Companion diagnostic test cleared to identify patients with susceptible FGFR mutations.

  • Draft guidance on transurethral laser ablation for bladder cancer

    The draft guideline is open for public comment until 18 April 2019

  • Bladder cancer: atezolizumab safe, effective in real-world study

    Findings from IMvigor211 are applicable to a broader, pretreated population.

  • MIBC: RC delay after NACT, TURBT tied to poorer survival

    Rural neighborhood and change in provider were associated with delays.

  • Load more